Fidelity Wise Origin Bitcoin Fund amends trust agreement to allow in-kind share transactions
Investing.com -- Polyrizon Ltd. (NASDAQ:PLRZ) stock surged 41% following the announcement of encouraging preclinical results for its PL-14 Allergy Blocker, which demonstrated targeted deposition in the nasal vestibule—a critical area for allergen interception.
The biotechnology company, focused on intranasal products, revealed that its proprietary Capture & Contain (C&C) platform achieved over 60% deposition in the nasal vestibule during tests conducted in collaboration with the University of Parma in Italy. This region is the first physiological area exposed to airborne allergens, making it a strategic target for blocking allergens before they trigger immune responses.
"We believe that the ability of our C&C platform to deliver a high concentration of hydrogel barrier to the vestibular region of the nose is a significant step forward," said Tomer Izraeli, CEO of Polyrizon. "These results support the core principle behind our blocker products—to form a protective layer at the point of allergen entry and prevent the initiation of allergic reactions."
The evaluation was led by Professor Fabio Sonvico from the University of Parma’s Department of Food and Drug, using a validated silicone-based human nasal cast and fluorescein-labeled imaging to assess spray deposition under clinically relevant conditions.
The global allergen blocker market was valued at $0.14 billion in 2024 and is projected to reach $0.21 billion by 2033, growing at a CAGR of 4.4%, according to Business Research Insights.
The company reported that the hydrogel formulation maintained favorable sprayability and coverage under standard administration angles, demonstrating practicality for self-administration. Polyrizon plans to continue preclinical validation before advancing toward clinical trials for its C&C platform.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.